Neurofibromatoses - Pipeline Review, H2 2016

  • ID: 4015275
  • Drug Pipelines
  • 71 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • Novartis AG
  • Plex Pharmaceuticals Inc
  • MORE
Neurofibromatoses - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses - Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses (Genetic Disorders) pipeline landscape.

Neurofibromatosis (commonly abbreviated NF; neurofibromatosis type 1 is also known as von Recklinghausen disease) is a genetically-inherited disorder in which the nerve tissue grows tumors (neurofibromas) that may be benign or may cause serious damage by compressing nerves and other tissues. The disorder affects all neural crest cells (Schwann cells, melanocytes and endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body, forming tumors; melanocytes also function abnormally in this disease, resulting in disordered skin pigmentation and café au lait spots. The tumors may cause bumps under the skin, colored spots, skeletal problems, pressure on spinal nerve roots, and other neurological problems.

Report Highlights:

The Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neurofibromatoses (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 3, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neurofibromatoses (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Neurofibromatoses (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neurofibromatoses (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neurofibromatoses (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses (Genetic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neurofibromatoses (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • Novartis AG
  • Plex Pharmaceuticals Inc
  • MORE
Introduction

Neurofibromatoses Overview

Therapeutics Development

Pipeline Products for Neurofibromatoses - Overview

Pipeline Products for Neurofibromatoses - Comparative Analysis

Neurofibromatoses - Therapeutics under Development by Companies

Neurofibromatoses - Therapeutics under Investigation by Universities/Institutes

Neurofibromatoses - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Neurofibromatoses - Products under Development by Companies

Neurofibromatoses - Products under Investigation by Universities/Institutes

Neurofibromatoses - Companies Involved in Therapeutics Development

Alexion Pharmaceuticals Inc

Arno Therapeutics Inc

AstraZeneca Plc

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Lixte Biotechnology Holdings Inc

Novartis AG

Plex Pharmaceuticals Inc

Neurofibromatoses - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AR-42 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

asfotase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-0158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FRAX-597 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icotinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OS-342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurofibromatoses Type I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-0524 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neurofibromatoses - Dormant Projects

Neurofibromatoses - Discontinued Products

Neurofibromatoses - Product Development Milestones

Featured News & Press Releases

May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Neurofibromatoses, H2 2016

Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Neurofibromatoses - Pipeline by Alexion Pharmaceuticals Inc, H2 2016

Neurofibromatoses - Pipeline by Arno Therapeutics Inc, H2 2016

Neurofibromatoses - Pipeline by AstraZeneca Plc, H2 2016

Neurofibromatoses - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016

Neurofibromatoses - Pipeline by Celldex Therapeutics Inc, H2 2016

Neurofibromatoses - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016

Neurofibromatoses - Pipeline by Novartis AG, H2 2016

Neurofibromatoses - Pipeline by Plex Pharmaceuticals Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Neurofibromatoses - Dormant Projects, H2 2016

Neurofibromatoses - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Neurofibromatoses, H2 2016

Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alexion Pharmaceuticals Inc
  • Arno Therapeutics Inc
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co Ltd
  • Celldex Therapeutics Inc
  • Lixte Biotechnology Holdings Inc
  • Novartis AG
  • Plex Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll